Drug intelligence / Profile preview

enoxaparin sodium

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules
Administration
Subcutaneous, Intravenous
01

Overview

Enoxaparin sodium is a low molecular weight heparin (LMWH) derived from porcine intestinal mucosa heparin. It exerts its anticoagulant effect by binding to and accelerating the activity of antithrombin III, which subsequently inhibits pro-thrombotic enzymes, primarily clotting factor Xa and, to a lesser extent, factor IIa (thrombin). This selective inhibition provides a predictable antithrombotic response with a lower risk of bleeding compared to unfractionated heparin. The First Affiliated Hospital of Chongqing Medical University is investigating the use of enoxaparin sodium for the short-term prevention of thrombosis in patients undergoing arteriovenous fistula (AVF) surgery, a procedure essential for hemodialysis access that is frequently complicated by early-stage stenosis or occlusion due to clot formation.

Brand names
LovenoxClexaneInhixaThorinane
Other names
low molecular weight heparin-First Affiliated Hospital of Chongqing Medical University-thrombosisenoxaparinLMWHlow molecular weight heparin
02

Targets

F2 (Thrombin)F10 (Factor Xa)ATIII (Antithrombin III)

Beyond the preview

Go deeper on enoxaparin sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enoxaparin sodium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call